Page 213 - Haematologica March 2020

17-gene LSC score: mutations and outcome in AML
between the groups. Patients with CBF-AML were much more frequently classified in the 17-genelow score group, especially those with a t(8;21)(q22;q22) who were never found to have a 17-genehigh score. As previously reported, patients with CBF-AML had a relatively favorable out- come compared with patients belonging to other cytoge- netic subgroups.37-41 On the other hand, patients in the 17- genehigh score group more frequently carried cytogenetic
AB
abnormalities associated with adverse outcome, such as a complex karyotype, especially a typical complex kary- otype,36 and inv(3)(q21q26) or t(3;3)(q21;q26).1,17,36,40-42 Of note, patients with inv(3) or t(3;3) were classified exclu- sively in the 17-genehigh score group.
Next, we looked for differences in the mutational pat- terns of 81 cancer- and leukemia-associated genes19 between 17-genelow and 17-genehigh score patients. Patients
CD
EF
Figure 3. Differences in outcome between younger adult patients (aged <60 years) with low and those with high 17-gene leukemic stem cell scores in the context of the current European LeukemiaNet 2017 classification. (A) Disease-free survival (DFS) and (B) overall survival (OS) of younger patients within the European LeukemiaNet (ELN) Favorable-risk group according to the 17-gene leukemia stem cell (LSC) score. (C) DFS and (D) OS of younger patients within the ELN Intermediate-risk group according to the 17-gene LSC score. (E) DFS and (F) OS of younger patients within the ELN Adverse-risk group according to the 17-gene LSC score.
haematologica | 2020; 105(3)
727